Why this keeps being confusing
If you’ve tried to figure out whether a given peptide is legal in 2026, you’ve probably come away more confused than when you started. Part of the reason is that the answer genuinely changed this year — and part is that a lot of marketing is describing where things might go as if it’s already settled.
Here’s a clean status check as of August 2026, with the hype stripped out. And here’s a useful tell before we start: in its early-August earnings call, the largest telehealth company in the country said it is waiting on the FDA before launching several of these peptides. When the biggest, best-funded, most motivated player says “we can’t do this yet,” that tells you most of what you need to know about the current legal reality.
The three buckets
The cleanest way to think about peptides right now is to sort them into three buckets by legal status.
Bucket 1 — Already available by prescription. Some peptides have an established prescription pathway today. Sermorelin (a growth-hormone-releasing peptide) is available through licensed prescribers and, in some cases, compounding pharmacies. Substances like NAD+ and glutathione are already used in clinical and wellness settings. These are the ones the big telehealth companies say they’ll roll out first — precisely because they don’t require a new FDA rule. “Available,” though, is not the same as “FDA-approved for anti-aging”; several of these uses are off-label.
Bucket 2 — Recommended by an advisory committee, but not yet legal to compound. This is the bucket everyone’s excited about, and the one most often misrepresented. In July 2026, an FDA advisory committee reviewed a group of peptides and recommended six of seven for possible compounding — including several popular in the recovery and longevity worlds. But an advisory recommendation is not a rule. The committee even went against the FDA’s own staff recommendation. Until the formal rulemaking process is complete, these peptides are not legal to compound, and that process typically takes many months to a couple of years.
Bucket 3 — Not recommended / no pathway. At least one peptide reviewed in that same process was not recommended, and many others have no compounding pathway at all. For these, the marketing-to-legality gap is widest.
What the July advisory vote did — and didn’t — do
Because this is where most of the confusion lives, it’s worth being precise.
What it did: a committee signaled that, in its view, several peptides could reasonably be considered for the list that permits compounding. That’s a meaningful directional signal.
What it did not do: it did not make anything legal. It did not bind the FDA, which is free to agree, disagree, or add conditions. It did not shorten the formal rulemaking that has to happen next. And it did not change what’s compoundable today, which is: not these peptides.
I’ll say the quiet part plainly, because a lot of sites won’t: a recommendation is not a rule, and nothing in that vote made a currently-illegal peptide legal to compound. Anyone selling you otherwise is ahead of the regulation.
The GLP-1 corner of this
The other moving piece is the GLP-1 medications — semaglutide and tirzepatide. Those aren’t in the same advisory bucket, but they’re part of the same “what’s legal to compound” question people are asking. The short version: the mass-compounding of GLP-1s that happened during the shortage has been winding down as the shortages resolved, and a separate FDA proposal affecting their compounding status has not been finalized. That’s why telehealth companies are moving customers from compounded to branded versions. If your compounded GLP-1 program is changing, that’s the reason.
How to read the marketing wave
You’re going to see a lot of confident peptide marketing over the next year as companies position for whatever the FDA ultimately decides. A few honest filters:
- “Recommended” is not “approved” is not “legal to compound today.” Watch for the slide between those.
- If a site is ready to sell you a bucket-2 peptide right now, ask how that squares with the fact that the rule permitting it doesn’t exist yet.
- Off-label is not illegal, but it’s not FDA-approved either. Both things can be true; a good provider will tell you which you’re in.
- Nobody credible can tell you what the FDA will finalize or when. Anyone predicting the outcome with confidence is guessing.
My position, and my scope
Two things to be clear about. First, I’m a Doctor of Acupuncture and Oriental Medicine — I don’t prescribe or compound peptides, and this article isn’t an offer to source anything. It’s education so you can navigate a genuinely confusing and fast-moving space without being sold ahead of the science or the law.
Second, my consistent stance through all of this has been to report what’s actually happening, explain what it does and doesn’t mean, state plainly that the unsettled things are unsettled, and not predict what regulators will do. That’s less exciting than “peptides are here” — and it’s the version that will still be accurate next quarter.
Frequently asked questions
Are peptides legal in 2026?
It depends on the peptide. Some (like sermorelin) have an existing prescription pathway. The group an FDA advisory committee recommended in July 2026 is not yet legal to compound — that requires formal rulemaking that isn’t finished.
Did the FDA approve BPC-157 and other peptides?
No. An advisory committee recommended several for possible compounding, against FDA staff’s own recommendation. A recommendation is not approval and does not make them legal to compound today.
When will the recommended peptides become legal?
No one can say for certain. Formal FDA rulemaking typically takes many months to a couple of years, and the outcome isn’t guaranteed. Be skeptical of confident timelines.
Why are telehealth companies waiting?
Because the biggest ones have said they can’t legally launch the listed peptides until the FDA completes its rulemaking. That’s the clearest signal that these aren’t available through legitimate channels yet.
What happened to compounded semaglutide?
The shortage-era mass compounding is winding down as shortages resolved, and companies are moving customers to branded versions. A separate FDA proposal on GLP-1 compounding has not been finalized.
The takeaway
As of August 2026: a few peptides have real prescription pathways, a larger group got an advisory thumbs-up that hasn’t yet become law, and plenty of marketing is describing the future as the present. The most-motivated companies in the industry are publicly waiting on the FDA — a good reason for you to be cautious about anyone who isn’t.
If you want an honest read on where a specific peptide actually stands and whether it fits your goals, book a consultation in Tustin or virtually. I’ll tell you what’s real, what’s hype, and what’s simply not settled yet.
Author: Dr. Brandon Bright, DAOM, LAc — Tustin, Orange County. Educational content; not medical or legal advice. A DAOM/LAc does not prescribe or compound peptides. Regulatory descriptions reflect public information as of August 2026; the situation is unsettled and evolving. Nothing here predicts FDA action or should be read as guidance to source peptides outside legal channels.
Work with Dr. Bright
Root-cause care combining Traditional Chinese Medicine pattern diagnosis with functional medicine testing — in person at the Tustin clinic or by virtual visit. Book a consultation.
Related reading
- Best Anti-Aging Peptides 2026: BPC-157, TB-500, Senolytics & Longevity Protocols
- Should You Start a GLP-1 in 2026? The Complete Patient Decision Framework
- Retatrutide and the TRIUMPH-1 Trial: What Lilly’s Next-Generation Weight Loss Drug Could Mean for You — A DAOM Patient Preview
- Peptide Therapy in Orange County: What It Is, What It Costs, and Who Should Consider It